BeiGene Announces BRUKINSA Is Approved In 50 Markets

BeiGene and NewBridge Pharmaceuticals To Bring BRUKINSA to Patients in MENA Region, Following Approval for Previously Treated Mantle Cell Lymphoma in Kuwait, Bahrain and Qatar BRUKINSA has Previously Been Approved by

byBenzinga Newsdesk

June 13, 2022

1 minute read

BeiGene and NewBridge Pharmaceuticals To Bring BRUKINSA to Patients in MENA Region, Following Approval for Previously Treated Mantle Cell Lymphoma in Kuwait, Bahrain and Qatar

BRUKINSA has Previously Been Approved by Regulatory Authorities in the U.S., China, the European Union, United Kingdom, Canada, Australia, South Korea and Switzerland

Notable Dexcom Insider Makes $3.06 Million Sale

By Benzinga Insights

Today, 2:48 AM

Andrew K Balo, * at Dexcom (NASDAQ:DXCM), made a large insider sell on September 9, according to a new SEC filing.

DXCM

Where Do Video Game Accounts, Purchases Go After The Player Dies?

By Chris Katje

Today, 2:48 AM

Video games and mobile games have risen in popularity over the years. The industry has also seen a rise in the amount spent through in-game purchases. This leaves the unlikely question of what happens to your video game account and the purchases after you die. A new patent could reveal the answer.

AAPL

B of A Securities Initiates Coverage On Cerevel Therapeutics Hldg with Buy Rating, Announces Price Target of $39

By Benzinga Newsdesk

Today, 2:48 AM

B of A Securities analyst Tazeen Ahmad initiates coverage on Cerevel Therapeutics Hldg (NASDAQ:CERE) with a Buy rating and announces Price Target of $39.

CERE

Another Competitor For Amgen As FDA Approves Mirati Therapeutics’ KRAS Inhibitor For Lung Cancer Setting

By Vandana Singh

Today, 2:48 AM

The FDA granted accelerated approval to Mirati Therapeutics Inc (NASDAQ:MRTX) Krazati (adagrasib), a targeted treatment option for adult patients with KRASG12C-mutated locally…

MRTX

BeiGene Announces BRUKINSA Is Approved In 50 Markets

Related Posts

Notable Dexcom Insider Makes $3.06 Million Sale

Where Do Video Game Accounts, Purchases Go After The Player Dies?

B of A Securities Initiates Coverage On Cerevel Therapeutics Hldg with Buy Rating, Announces Price Target of $39

Another Competitor For Amgen As FDA Approves Mirati Therapeutics’ KRAS Inhibitor For Lung Cancer Setting